Thyroid Nodule Evaluation: Bethesda Classification, Molecular Testing, and When to Biopsy
Ultrasound Risk Stratification: ACR TI-RADS
The ACR Thyroid Imaging Reporting and Data System (TI-RADS) assigns points based on five ultrasound categories: composition (0-2 points), echogenicity (0-3), shape (0-3), margin (0-3), and echogenic foci (0-3). Nodules scoring TR1 (benign, 0 points) or TR2 (not suspicious, 2 points) do not require FNA regardless of size. TR3 nodules (mildly suspicious, 3 points) warrant FNA at 2.5 cm or greater, TR4 (moderately suspicious, 4-6 points) at 1.5 cm, and TR5 (highly suspicious, 7+ points) at 1.0 cm. This system reduces unnecessary biopsies by approximately 30% compared to older ATA guidelines.
Bethesda System for Reporting Thyroid Cytopathology
The Bethesda System (third edition, 2023) classifies FNA results into six categories with associated malignancy risks: Bethesda I (nondiagnostic, 5-10% malignancy risk), Bethesda II (benign, 0-3%), Bethesda III (atypia of undetermined significance/AUS, 10-30%), Bethesda IV (follicular neoplasm, 25-40%), Bethesda V (suspicious for malignancy, 50-75%), and Bethesda VI (malignant, 97-99%). The updated third edition revised the implied malignancy risk for Bethesda III upward, reflecting real-world data showing higher cancer rates than initially estimated.
For Bethesda I results, repeat FNA should be performed after 4-6 weeks. Bethesda II nodules undergo surveillance ultrasound at 12-24 months. Bethesda V and VI typically proceed to surgery. The clinical dilemma concentrates on Bethesda III and IV, where molecular testing has become the critical decision tool.
Molecular Testing in Indeterminate Nodules
The two dominant commercial platforms are the Afirma Genomic Sequencing Classifier (GSC) and ThyroSeq v3. Afirma GSC functions primarily as a rule-out test with a negative predictive value of 96% for Bethesda III and 95% for Bethesda IV nodules. A benign Afirma result supports observation over surgery. ThyroSeq v3 analyzes 112 genes and functions as both a rule-in and rule-out test, with sensitivity of 94% and specificity of 82% in the indeterminate cytology population. A negative ThyroSeq result carries a residual cancer risk of approximately 3%.
Sponsored
Surgical Decision-Making and Active Surveillance
For confirmed papillary thyroid microcarcinomas (≤1 cm) without extrathyroidal extension or lymph node involvement, active surveillance is now an accepted alternative to surgery, supported by Japanese prospective data (Kuma Hospital) showing that only 8% of observed microcarcinomas grew by 3 mm or more over 10 years. The ATA guidelines endorse active surveillance for appropriately selected low-risk patients who prefer to avoid surgery.
TSH and the Malignancy Correlation
Multiple studies have demonstrated a linear relationship between TSH levels and thyroid cancer risk. Patients with TSH in the upper quartile of the normal range have a 2-3 fold higher risk of malignancy in biopsied nodules compared to those with low-normal TSH. While this association does not independently change biopsy thresholds, it adds to the risk stratification calculus, particularly in Bethesda III/IV nodules where the molecular testing result is equivocal. A suppressed TSH should also prompt radioiodine uptake scanning to evaluate for autonomous function, as hot nodules carry a malignancy risk below 1%.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.